Anti-HIV Agents

"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.

Descriptor ID	D019380
MeSH Number(s)	D27.505.954.122.388.077.088
Concept/Terms	Anti-HIV Agents Anti-HIV Agents Agents, Anti-HIV Anti HIV Agents Anti-AIDS Agents Agents, Anti-AIDS Anti AIDS Agents Anti-HIV Drugs Anti HIV Drugs Drugs, Anti-HIV AIDS Drugs Drugs, AIDS Anti-AIDS Drugs Anti AIDS Drugs Drugs, Anti-AIDS

Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Anti-Infective Agents [D27.505.954.122]
Antiviral Agents [D27.505.954.122.388]
Anti-Retroviral Agents [D27.505.954.122.388.077]
Anti-HIV Agents [D27.505.954.122.388.077.088]

Below are MeSH descriptors whose meaning is related to "Anti-HIV Agents".

Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.

Bar chart showing 296 publications over 30 distinct years, with a maximum of 15 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	0	2
1997	6	3	9
1998	3	1	4
1999	12	1	13
2000	6	4	10
2001	7	4	11
2002	5	3	8
2003	6	4	10
2004	6	4	10
2005	12	2	14
2006	9	3	12
2007	7	3	10
2008	10	0	10
2009	5	2	7
2010	8	3	11
2011	7	1	8
2012	11	2	13
2013	7	4	11
2014	6	4	10
2015	11	3	14
2016	6	2	8
2017	9	3	12
2018	12	1	13
2019	9	5	14
2020	4	4	8
2021	15	0	15
2022	6	0	6
2023	8	0	8
2024	10	3	13
2025	2	0	2

Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.

Maguire C, Rueve K, Farmer E, Huesgen E, Karaj A, Binkley A, Mounzer K, Brizzi M, Chary P, Sung P, Graziani A, Hiserodt E, Baron J, Koenig H, Short WR. Real World Virologic Outcomes in Patients With Elevated Body Mass Index Receiving Long Acting Cabotegravir/Rilpivirine. Clin Infect Dis. 2025 Aug 01; 81(1):67-74.

View in: PubMed
La Via L, Marino A, Cuttone G, Nunnari G, Deana C, Tesauro M, Voza A, Planinsic R, Longhitano Y, Zanza C. Critical Care Pharmacology of Antiretroviral Therapy in Adults. Eur J Drug Metab Pharmacokinet. 2025 Mar; 50(2):105-118.

View in: PubMed
Dawit R, Goedel WC, Chang HY, Nunn AS, Chan PA, Doshi JA, Dean LT. County-Level Factors Associated with Reversal of Insurer-Approved HIV Pre-Exposure Prophylaxis Prescriptions in the United States, 2018. AIDS Behav. 2025 Apr; 29(4):1089-1095.

View in: PubMed
Atuhaire B, Muteebwa L, Nabunya R, Muhindo R, Ngabirano TD, Osingada CP, Muwanguzi PA. Brief Communication:?Factors associated with willingness to use long-acting injectable Cabotegravir for HIV pre-exposure prophylaxis (PrEP) among female undergraduate students at a Ugandan university. AIDS Res Ther. 2024 Dec 20; 21(1):95.

View in: PubMed
Short WR, Zimmerman MM, Mohamed O, Mofenson LM. Safety Data Timelines for Pregnant Individuals With HIV on Antiretroviral Therapy. Clin Infect Dis. 2024 12 17; 79(6):1472-1474.

View in: PubMed
Holt LM, Short WR, Momplaisir F, Hyun E, McKinney J, Lugo Morales A, Duque A, Druyan B, Ndubizu C, Duthely L, Joseph N, Sheth AN, Badell ML. Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes. Clin Infect Dis. 2024 11 22; 79(5):1258-1261.

View in: PubMed
Keddem S, Broderick K, Van Epps P, Roberts CB, Chhatre S, Beste LA. Brief communication: The cohort of women prescribed HIV PrEP at the Veterans Health Administration. AIDS Res Ther. 2024 Nov 01; 21(1):78.

View in: PubMed
Bakre S, Chang HY, Doshi JA, Goedel WC, Saberi P, Chan PA, Nunn A, Dean LT. Clinician Specialty and HIV PrEP Prescription Reversals and Abandonments. JAMA Intern Med. 2024 Oct 01; 184(10):1204-1211.

View in: PubMed
Dawit R, Predmore Z, Raifman J, Chan PA, Dean LT. Perceived Versus Actual Costs of HIV Pre-Exposure Prophylaxis Among Gay, Bisexual, and Other Men Who Have Sex with Men in the United States. AIDS Patient Care STDS. 2024 Oct; 38(10):468-476.

View in: PubMed
Zang X, Ankrom W, Kraft WK, Vargo R, Stoch SA, Iwamoto M, Matthews RP. Intracellular islatravir-triphosphate half-life supports extended dosing intervals. Antimicrob Agents Chemother. 2024 09 04; 68(9):e0045824.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement